Addison Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Addison Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8	Closed	-$13	–	697
2023 Q2	$13	Hold	8	–	–	﹤0.01%	627
2023 Q1	$14	Hold	8	–	–	﹤0.01%	625
2022 Q4	$15	Hold	8	–	–	﹤0.01%	783
2022 Q3	$0	Buy	+8	New	+$34	﹤0.01%	790

Addison Advisors's NBRV Position: Q3 2023 in Review

Addison Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2023, closing a stake of 8 shares — an estimated $13 sold.

Addison Advisors first reported a position in NBRV in Q3 2022 and held it in 4 quarters. The position peaked at $15 in Q4 2022. 0 funds tracked by Wall St. Rank hold NBRV as of Q3 2023.

Addison Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2023 after selling out during the quarter.
Addison Advisors sold 8 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2023, an estimated $13.
Addison Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2022 and held it in 4 quarters.
Addison Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $15 in Q4 2022.
0 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2023.

Based on Addison Advisors's 13F filing for Q3 2023, filed 7 Nov 2023.